Eleven Vials of One Person

The first solo release of my career was eleven vials of one person’s liver enzyme.

The paperwork calls it an Individualized Investigational Therapy, which is a real category now, and a grave is one too. It exists for exactly one situation: an error in a single genome, a child who is the only person on Earth carrying that particular sequence, a trial with no comparator arm. There is no market, because there is no second patient. There is no second run planned, because the run is that child’s body and nothing else. The mechanism is plausible. I have spent nine years in this building earning a doctorate in that word, and it still means what it meant when I was twenty-six: we do not know. Therapies like this one fail more often than they succeed, if anyone is counting, and by the time the file reaches my desk nobody is counting. I am the one who signs anyway.

The child is the trial, formally. Before the first dose, the graph has zero points on it.

The child’s name, in the file, is the patient identifier. That is standard. The mother’s name is on the consent forms, which is human. I sign the certificate.

FILL

Dani filled the vials at 05:40 on a Tuesday.

She is the fill operator. In nine years she has moved more than ten thousand vials through the line, more than a hundred products, and she does it alone in the clean room, arms in the glove ports, head down in the airflow. I have watched her through the glass for nine years and she has never once looked back at me. I used to take it for coldness. Then I learned what the zone of turbulence does to a loose eyelash, and it stopped seeming to have anything to do with me.

This fill took two hours, long for eleven vials, because she handled each one like a full campaign. Pipette, balance, then the inspection herself, black background and white. A robot does this step in most facilities now. For eleven vials the robot costs more than the operator, so Dani does it by hand, and the batch record will describe this as an operator controlled step rather than as Dani. She held each vial up to the light longer than the compendium requires. The compendium is written against ten thousand units at a time. She was looking at eleven. Two vials were pulled for sterility, one for the archive, which left eight, the dose: four now, four at day 90, if the day 30 number is right.

Each vial held 1.2 mL of a pale liquid that used to be part of her. Cells from a biopsy, the gene corrected at one position, the corrected cells grown in a tank, the enzyme harvested and purified and hitched to a sugar the liver pulls out of the blood, because the liver is where the work happens. Three years of a company’s existence, ending as eleven vials at minus seventy degrees in a clean room in an office park.

If you put those molecules into anyone else, the immune system would take them apart before they reached the liver, because the protein is hers, and the body tolerates what it recognizes. The drug is as singular as the patient. There is no second child.

In the airlock afterward, Dani pulled her hands out of the ports and said, “I held the last one too long.” Nine years, and that is the closest I have seen her come to prayer.

CLEANING

Before the fill there was the cleaning, and the cleaning is where the industry turns into a religion.

Everything the product would touch got swabbed, and everything it might touch, and everything it might not touch but might as well have. The swabs went to the bioburden lab, the rinse water to the carbon analyzer, and both to the endotoxin lab, because the fever that is not a fever comes out of nowhere and ends the world. We photographed the entire line under ultraviolet light like a crime scene. Nobody has ever produced one of those photographs in a dispute I have heard about.

The line passed on the first try, and I signed the validation without a flicker of doubt, because the line was never the risk. The risk was a child of two meeting a molecule that had never existed before, with nine years of my profession standing in between, agreeing that it would probably be fine.

The line’s entire output for the month was eleven vials, and we documented the cleanliness of the line like it would run forever. Tomorrow the line runs a generic, and the cleaning will be identical, and the signatures will be identical, and the output will be divided among forty thousand strangers, and nobody will photograph the bench. I have signed cleaning validations for nine years and never understood why the religion only shows up on the days when the product is singular. The swabs are the same swabs. We just usually do not have to mean it.

MONEY

The price came out on a Thursday in a conference room with a view of the parking garage.

The sponsor was a company that had never made a drug and will never make this one again, and the program director put up a slide with a number on it, and the number was eleven million dollars for one survival. A small country’s health budget, minus the country. The breakdown underneath was a ledger of what one person costs when the market cannot spread her across strangers.

Three years of process development. A cell line with a patent. Assays they had to invent, because no kit on the shelf tests a protein that has only ever existed in one body. A tox program in a mouse engineered with her exact error, a mouse that gets the disease on schedule, and she never will. Three development lots that failed the purity spec and were written off, which in this business is the only thing that ever goes down the drain. A stability program that will run five more years, documenting the slow decay of eleven vials that will not exist anymore, for an archive nobody will ever ask for. The lawyers on both ends of the IND. The cold chain. The insurance. Whatever a company costs per day when it is not making anything. All of it, divided by one.

The last drug I released had a list price of four dollars and change, and it will be given to forty thousand people a year. This release will be identical to that one. Same suite, same process, same signature block. The market had reached down into the guts of the line and priced everything in the room that afternoon except the child, who was not in the building and has no cost code.

I did my own arithmetic while the director talked, which pharmacists do when someone else is doing the talking. Two hundred and fourteen hours of my time on this program at a fully burdened rate, my wage plus the building plus the insurance plus the air I breathe indoors: about twenty-three thousand dollars of me is in that slide. The goods, the vials and the enzyme and the freezers and the shipper, came to about ninety-four thousand. A hundred thousand dollars of things, eleven million of everything else, and somewhere in the middle, my name.

Elise’s mother came to the facility once, that week, during the release testing. She wanted to see the room where her daughter’s treatment had been handled, and the program director asked me to walk her down, because I was the one who would sign, and I think she wanted to see the signature too, though she never said so.

She wore a visitor badge and a coat she did not take off, and she stood at the glass with me while the line ran a media fill, which is what the line does when it is proving it can be clean. She watched the operator work for a long time, arms in the glove ports, head down in the airflow, and then she asked the question nobody on the project had been willing to say out loud. What happens if it does not work.

Everyone with a piece of the answer found something else in the room to look at. The mother said, “It’s all right. I know the answer. I wanted to see if you did.”

I told her the molecular biology of her daughter was elegant and correct and almost certainly not enough, and that we would know in 30 days, and she thanked me. There were eight vials left in the world at the time, all of them hers. She looked at the freezer door and did not ask to be closer to them.

She asked me what the second dose was for, and I told her it was the booster, the half that holds the number down after the first half has done the work. She nodded. “She takes her medicine every morning,” she said. “Like it’s a job. She’s two.” The medicine she meant was the one that costs eleven dollars a month and tastes like chalk, the one she will take every morning for the rest of her life if the expensive one does not work. I did not say that. She was standing in the room where the other one had been filled.

As she left she stopped at the observation window and put her hand flat against the glass, and I did not tell her that the print would be gone before her daughter’s first dose.

RELEASE

The release testing came back over three days, which is fast for the things that matter and normal for the things that do not.

Appearance: clear, no visible particles. Identity: the mass spec weighed the protein, and the protein was the corrected sequence, the one wrong letter put back where it belonged. Potency: the enzyme did the thing enzymes do, at a rate the archive called normal, for a reference that is a box of papers about a protein that will never be standardized. Endotoxin below the limit that gives a child a fever with a cause. pH, osmolality. Everything passed.

Sterility takes 14 days. The infusion is Saturday. The protocol allows the release with the sterility still cooking, with three signatures on the disposition: the treating physician, the family, and the release pharmacist, which is me. The family signed in a hospital room. The physician signed in a hallway, on a clipboard, standing up. I signed in my office at 16:42, on the certificate of analysis, with a ballpoint borrowed from the front desk, and I am grateful for that pen, because it was the one object in the entire program that was not a ritual.

I read the certificate three times and signed it once. It is one page, with a watermark and a lot number, and a signature block the same size as the physician’s. I have signed nine hundred and thirteen of them and never once understood what I was for. I am the last person between the molecule and the child. After my signature comes the shipper, the courier, the pharmacy, the line, the needle, the hour, and none of it is mine to change. There is no decision left in any of it, and there never was. The information was her whole body, and we had spent three years reading it.

If the sterility comes up positive on day 14, the call will arrive after the infusion, and it will not change the medical record. It will only change my memory of the signature. I signed anyway. The infusion was booked for Saturday, and Saturday does not wait on a laboratory.

Before the packing I held one of the vials. It was cold, and it was light, and the entire program fit in my palm and weighed almost nothing. Then it went into a dry shipper the size of a small suitcase, with a temperature logger and a manifest and a phone number in permanent marker, and a kid from the courier service took it out on a dolly like it was laundry. The dolly had a squeaky wheel. He did not know what he was carrying. He took it down the ramp and out to the van, and I watched him drive away. The temperature logger was already reporting, and the phone number on the manifest was mine. I have never been called on that number. In my experience the couriers know anyway, and nobody wants to be the one to say it out loud.

HOME, 03:10

That night my daughter had a fever, 38.2, and the house was dark, and I measured her dose by her weight at the kitchen counter, the first thing you learn about dosing a child and the only thing you keep: 10 milligrams per kilogram, drawn from the bottle into the syringe, checked against the light. She took it half asleep and turned her face away, and I wiped the corner of her mouth with my thumb. The week before I had released an amount of one person’s enzyme priced at eleven million dollars.

My wife surfaced long enough to ask if the day had been long, and I said it had been fine, which it had; the certificate had been fine too. She went back under. I stood over my daughter’s bed until her breathing evened out. In the file, Elise’s breathing was a number on a graph, and the graph had no points on it yet, and I had signed the thing that would put the first point there.

I stood at the counter with the syringe in my hand.

DAY 30

On day 30 I was copied on the readout, because my name is in the file, and my name travels with the lot; the batch number does too. I read the subject line in the parking lot with the engine off.

Baseline phenylalanine: 1,140 micromoles per liter, a number the body was never meant to see. The top of the reference range is 80. Day 30: 210.

Still two and a half times the top of the range. Also down 82 percent. The protocol says the therapy continues if the value has fallen at least 40 percent by day 30. It continues. The second dose goes at day 90, and it goes without me. The paperwork is already signed. The sterility came back clean on day 14, and I noted it in the margin and did not celebrate, because it was not the number I was waiting for.

The readout goes to the physician first, and the physician calls the family, and then the file lands in my inbox, by which time it is already a fact. I signed the thing that made the fact. I found out about it after the mother did.

I sat in the car and did the arithmetic again, because that is what I do when something matters. Eleven million dollars. Twenty-three thousand dollars of me. Ninety-four thousand of things. One child, one graph, and one point on it now, going down.

Divide by one. They teach you never to divide by one, because the whole art of my profession is the big denominator, the lot big enough to anonymize, and this lot would not divide. It had to be spent entire, all of it on one body.

The generic next week, the forty thousand strangers who will never know my name, and I will not remember theirs either. The nine hundred and thirteen lots before this one, every one of them read three times and signed once. The second dose was already in a hospital freezer, signed for, paid for, waiting on a date that had just become real. I have signed for a hundred lots that were waiting on a day. This is the first one I wanted to see arrive.

I went inside. My daughter was asleep, her forehead cool against my palm. The readout went into the folder with the rest of my work. I have signed nine hundred and fourteen certificates of analysis. I can still give you the lot number and the name on one of them, and I have never worked out whether that is the job working or the job failing.